Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Laser-Enhanced Anti-VEGF Precise Penetration (LEAP) Strategy for Neovascular Age-Related Macular Degeneration: A Multicentre, Prospective, Stratified Block-Randomised Controlled Trial

NCT07744204 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT07744204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07744204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Laser-Enhanced Anti-VEGF Precise Penetration (LEAP) Strategy for Neovascular Age-Related Macular Degeneration: A Multicentre, Prospective, Stratified Block-Randomised Controlled Trial
Lead sponsor
Chinese PLA General Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
July 31, 2029
Enrollment
240 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration(namd), wet macular degeneration